• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

ObvioHealth Launches Digital Therapeutics API for Clinical Trials

by Fred Pennic 02/24/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– ObvioHealth launches proprietary application programming interface (API) tailored specifically for digital therapeutics (DTx) clinical trials.

– ObvioHealth’s API ensures tight integration between the digital therapeutic and the ObvioGo platform, providing sponsors with accurate data to correlate efficacy with adherence to the DTx. In addition, ObvioGo’s integration reduces participant task duplication because—in most cases—outcomes can be passively captured directly from the DTx.

– The API provides DTx sponsors with a “plug and play” integration to ObvioHealth’s ObvioGo® platform, enabling the capture of more objective adherence and efficacy data while also reducing burden for clinical trial participants. 

Challenges in Digital Therapeutics

DTx clinical trials present unique challenges when it comes to measuring adherence and efficacy. To determine adherence, sponsors must consider duration and frequency of DTx use and compliance with the DTx tasks. Some clinical trials might measure these factors through patient-reported questionnaires. However, this method can bias the data because 1) declared behaviors can be inaccurate, and 2) the questionnaires can trigger a participant to use the DTx, thus influencing their real-world behaviors.  

“Adherence in a DTx trial isn’t as simple as recording whether a participant took a pill or didn’t. Instead, you need to capture the level of interaction between the participant and the DTx,” said Craig Gravina, Chief Technology Officer at ObvioHealth. “This requires data to be captured directly from the source—the DTx itself—without prompts that might influence the participant’s behavior.” 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: API, behavior, Clinical Trial, Clinical Trials, Digital Therapeutics, ObvioHealth

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |